Investigational drug · Phase 2
IPN60350
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasms, Neoplasm Metastasis, Neoplastic Processes.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IPN60350"
First trial start
2026
Dec 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IPN60350", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasms
- Neoplasm Metastasis
- Neoplastic Processes
- Pathologic Processes
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IPN60350" as an intervention, largest first.
- A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid TumorsPivotal-lookingNot yet recruiting
IpsenIndustry
NCT07944144 · 205 participants (planned) · Start Dec 1, 2026 · Primary completion Jun 28, 2030
Drug: IPN60350 · For: Neoplasms; Neoplasm Metastasis; Neoplastic Processes and 1 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Neoplasms
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- [177Lu]Lu-NeoBLutetium NeoB, [177Lu]-NeoBPhase 22 trials
Novartis · Breast Cancer, Neoplasms
- [68Ga]Ga-NeoBGallium NeoB, [68Ga]-NeoBPhase 22 trials
Novartis · Breast Cancer, Neoplasms
- Checkpoint InhibitorPhase 22 trials
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- AdAPT-001Phase 21 trial
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- CORT125236NenocorilantPhase 21 trial
Corcept Therapeutics · Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.